Azurity Pharmaceuticals Absorbs Slayback Pharma
September 29, 2023
Source: drugdu
91
The company expects to yield a significant number of new medicine launches from the acquisition.
Azurity Pharmaceuticals, Inc. broke the news that it has officially acquired Slayback Pharma LLC from existing investors including KKR and Everstone Capital, making it a wholly owned subsidiary. According to Azurity, the acquisition is expected to realize its purpose of serving overlooked patients, hoping to yield a significant number of new medicine launches over the coming years.
"I am delighted to announce this combination and the increased potential it brings to do more for overlooked patients," said Richard Blackburn, CEO, Azurity. "The complementary expertise of the two companies in developing innovative dose forms will result in a strong pipeline of new medicines to meet the needs of patients. We will bring the commercial expertise of Azurity to Slayback's pipeline and look forward to introducing an even wider range of dose-forms and formulations to meet a broader set of patient needs."
Copyright©2024 Ddu. All rights reserved.
Read more on
- Ultrasound-Aided Blood Testing Detects Cancer Biomarkers from Cells May 17, 2024
- New DNA Origami Technique to Advance Disease Diagnosis May 17, 2024
- Blackstone Unveils Immunology Startup With $300M and a Phase 2-Ready Drug From Merck May 17, 2024
- FDA Approves Roche’s HPV Self-Collection Solution, Allowing Patients to Gather Their Own Samples in a Healthcare Setting May 17, 2024
- US study reveals interferon combinations cause lupus symptoms and affect treatment May 17, 2024
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
